RxDoctor Payments Data

Nicholas Poponea, DO

Critical Care Medicine · Scottsdale, AZNPI 1538579776

Payments from drug & device makers

$629in general payments, 2019–2025

Across 16 payments — averaging $39.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$122
  • Johnson & Johnson$102
  • Genentech USA, Inc.$100
  • Actelion Pharmaceuticals US, Inc.$96
  • Takeda Pharmaceuticals U.S.A., Inc.$51
  • GSK$48
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$52984%
  • Education$10016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$629 in reported general payments places this provider in the 55th percentile of 175 critical care medicine providers in Arizona.

See all critical care medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$125,173
Medicare patients
340
Services billed
926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$54,006
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$31,840
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$6,833
BreynaBudesonide/Formoterol Fumarate34$6,671
SymbicortBudesonide/Formoterol Fumarate17$3,946
Albuterol Sulfate HfaAlbuterol Sulfate87$2,077
Azithromycin14$339
Montelukast Sodium16$257
Fluticasone Propionate19$231
Prednisone25$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$48$54,00675 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 175 critical care medicine providers in Arizona.

Other critical care medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →